Immunogenicity of a single dose of BNT162b2, ChAdOx1 nCoV-19, or CoronaVac against SARS-CoV-2 delta and omicron variants among previously infected adults: A randomized trial - 06/09/22

Suvimol Niyomnaitham ^{a, b}, Zheng Quan Toh ^{c, d}, Paul Vincent Licciardi ^{c, d}, Patimaporn Wongprompitak ^e, Kanjana Srisutthisamphan ^f, Katherine Kradangna Copeland ^g, Kulkanya Chokephaibulkit ^{b, h, ⁎}

^a Department of Pharmacology, Faculty of Medicine Siriraj Hospital, Mahidol University, Bangkok 10700 Thailand 

^b Siriraj Institute of Clinical Research (SICRES), Faculty of Medicine Siriraj Hospital, Mahidol University, Bangkok 10700, Thailand 

^c Infection and Immunity, Murdoch Children's Research Institute, Parkville, Victoria 3052 Australia 

^d Department of Pediatrics, The University of Melbourne, Parkville, Victoria 3010 Australia 

^e Department of Immunology, Faculty of Medicine Siriraj Hospital, Mahidol University, Bangkok 10700 Thailand 

^f National Center for Genetic Engineering and Biotechnology (BIOTEC), National Science Development Agency (NSTDA), Pathum Thani 12120 Thailand 

^g Mahidol University International College, Mahidol University, Salaya, Nakhon Pathom 73170 Thailand 

^h Department of Pediatrics, Faculty of Medicine Siriraj Hospital, Mahidol University, Bangkok 10700 Thailand 

^⁎Corresponding author at: Kulkanya Chokephaibulkit, MD. Professor of Paediatrics, Department of Paediatrics and Siriraj Institute of Clinical Research (SICRES), Faculty of Medicine Siriraj Hospital, 2 Wanglang Road, Bangkoknoi, Bangkok 10700, Thailand.Professor of PaediatricsDepartment of PaediatricsFaculty of Medicine Siriraj HospitalMahidol UniversitySiriraj Institute of Clinical Research (SICRES)2 Wanglang Road, BangkoknoiBangkok10700Thailand